Drug Profile
Research programme: anti-T-bet therapeutics - sterna biologicals
Alternative Names: SB 020; SB 021Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator sterna biologicals
- Class Antipsoriatics; Catalytic DNA; Enzymes
- Mechanism of Action T-Box transcription factor TBX21 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Psoriasis
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Germany
- 28 Aug 2022 No recent reports of development identified for preclinical development in Psoriasis in Germany
- 25 Jul 2018 Preclinical development is ongoing in Germany (sterna biologicals pipeline, July 2018)